Kamada Ltd. (NASDAQ:KMDA) Short Interest Update

Kamada Ltd. (NASDAQ:KMDA) was the target of a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 16,100 shares, a decline of 13.9% from the September 15th total of 18,700 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 37,300 shares, the short-interest ratio is presently 0.4 days.

Institutional Investors Weigh In On Kamada

An institutional investor recently raised its position in Kamada stock. Y.D. More Investments Ltd lifted its stake in shares of Kamada Ltd. (NASDAQ:KMDA) by 1,956.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 726,161 shares of the biotechnology company’s stock after buying an additional 690,842 shares during the period. Y.D. More Investments Ltd owned about 1.26% of Kamada worth $3,643,000 as of its most recent SEC filing. Institutional investors own 20.38% of the company’s stock.

Kamada Price Performance

NASDAQ KMDA opened at $5.27 on Wednesday. The business has a fifty day moving average price of $5.42 and a two-hundred day moving average price of $5.40. Kamada has a fifty-two week low of $4.08 and a fifty-two week high of $6.53. The stock has a market capitalization of $302.92 million, a PE ratio of 22.91 and a beta of 1.06.

Kamada (NASDAQ:KMDA) last released its earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. Kamada had a return on equity of 6.15% and a net margin of 9.75%. The firm had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $39.70 million. As a group, sell-side analysts expect that Kamada will post 0.26 earnings per share for the current year.

Analyst Upgrades and Downgrades

KMDA has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, August 15th. StockNews.com cut Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 27th. Finally, Stifel Nicolaus started coverage on Kamada in a research note on Wednesday, July 3rd. They set a “buy” rating and a $18.00 target price for the company.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.